Hormone replacement therapy: assessing your cardiovascular risk

For a healthy woman younger than 60 or within 10 years of menopause, systemic HRT used to treat symptoms generally has a favorable benefit-risk profile. Starting later is associated with higher risks of coronary events, stroke, and venous thromboembolism.

That distinction matters because HRT is sometimes discussed as if it were either broadly heart-protective or broadly dangerous. Neither conclusion is clinically useful. A hormone therapy cardiovascular risk assessment is a review of timing, route, symptoms, and measurable risk factors before a treatment decision. HRT is used to manage menopausal symptoms; it is not prescribed to prevent heart disease.

The timing hypothesis: why initiation windows matter

The cardiovascular profile of systemic HRT changes with age and time since menopause. In healthy women who start treatment before age 60 or within 10 years of menopause onset, the overall benefit-risk profile for symptom management is generally favorable. This is often called the timing hypothesis: the same treatment may have a different risk profile depending on when it begins.

Initiation after age 60 or more than 10 years after menopause is associated with increased risks of coronary events, stroke, and venous thromboembolism. These are population-level patterns, not a personal prediction. They do not mean every woman over 60 must avoid HRT, or that treatment started earlier eliminates cardiovascular risk. Age and timing shape the discussion; they do not replace an assessment of blood pressure, lipids, smoking, diabetes, prior vascular events, and other relevant clinical factors.

The purpose of treatment also matters. Systemic HRT may be considered when vasomotor symptoms, such as hot flashes and night sweats, are sufficiently disruptive to warrant treatment. The expected symptom benefit is weighed against the patient’s individual risks. A prescription should not be justified by the possibility of preventing a future heart attack.

For menopause heart health screening, the practical questions are:

• How old are you, and how long has it been since your final menstrual period?
• Are you considering treatment for symptoms, or expecting it to prevent cardiovascular disease?
• Do you have diagnosed cardiovascular disease, a history of stroke or venous thromboembolism, or uncontrolled risk factors?
• What are your current blood pressure and lipid results?
• Which estrogen route and, if needed, progestogen are being considered?

These details establish the clinical context. They also help separate the effect of a treatment from the cardiovascular risks already present before treatment begins.

Timing is part of the risk assessment. It does not make HRT a cardiovascular prevention drug.

Defining the safety thresholds for systemic hormone therapy

A useful assessment begins with baseline cardiovascular risk, rather than with a decision about a particular brand or dose. A 10-year cardiovascular disease risk of 10% or higher is considered a high-risk marker in guidance on systemic HRT. Uncontrolled risk factors also change the safety profile. Thresholds cited for particular concerns include blood pressure at or above 180/110 mmHg, total cholesterol above 7.8 mmol/L, and triglycerides above 4.5 mmol/L.

These cutoffs are clinical warning signals, not a substitute for judgment. A result near a threshold should be interpreted alongside the complete medical history, repeat measurements where appropriate, medications, and the reason systemic treatment is being considered. A blood pressure reading is affected by measurement conditions; lipid results need to be interpreted in context. A single number cannot fully describe a person’s cardiovascular risk.

The distinction between systemic and local hormone treatment also matters. Systemic estrogen reaches the circulation and is used when symptoms require a body-wide effect. Local vaginal estrogen is generally considered for genitourinary symptoms, such as vaginal dryness or discomfort with sex, and has a different exposure profile. The risks and treatment goals should not be blurred together under the single label “hormones.” The clinician should clarify which symptoms are being treated and which formulation is under consideration.

If cardiovascular risk is high, that does not automatically answer every treatment question. It does mean the potential symptom benefit, treatment route, alternatives, and current control of risk factors need closer review. In some situations, the safest next step is to address uncontrolled blood pressure or other risks before deciding whether systemic HRT is appropriate.

Transdermal versus oral estrogen: implications for clot and stroke risk

The route of estrogen delivery affects risk. Transdermal estradiol, delivered through the skin, is associated with lower risks of venous thromboembolism and stroke than oral estradiol. That difference is clinically relevant when a patient has elevated thrombosis or stroke risk and systemic HRT is being considered.

Oral and transdermal estrogen should therefore not be treated as interchangeable from a vascular-risk perspective. The route can change the risk discussion, although it does not erase the effects of age, timing, dose, or underlying disease. A lower relative risk with transdermal treatment is not the same as zero risk, and it does not establish that any route is suitable for every patient.

The route decision belongs in the same conversation as the baseline risk assessment. If systemic HRT is appropriate for symptoms, a clinician may favor transdermal estradiol when thrombotic or stroke risk is elevated. That preference is not a way to bypass assessment of established cardiovascular disease or uncontrolled risk factors. The evidence supports a difference between routes; it does not justify a blanket assurance of safety.

This is also why a request for estrogen therapy and stroke risk information should not be answered with a single warning about all estrogen. The formulation and route matter. So does whether the treatment is systemic, the timing of initiation, and the patient’s clinical history.

Progestogen selection and vascular health

For a patient with a uterus who uses systemic estrogen, a progestogen is generally part of the treatment plan to protect the endometrium. Its selection can contribute to the overall vascular-risk discussion. Non-androgenic progestogens, including micronized progesterone and dydrogesterone, show neutral or lower cardiovascular and venous thromboembolism risk compared with synthetic androgenic progestogens.

That comparison does not mean every progestogen has identical effects, nor that one option removes the cardiovascular risks associated with systemic estrogen. The complete regimen matters: estrogen route, progestogen type, treatment indication, timing, and the patient’s risk factors should be considered together.

When discussing menopause hormone therapy safety, ask the prescriber to identify the exact components of the regimen. “HRT” alone is too broad a description to assess. A clinically useful conversation specifies whether estrogen is oral or transdermal, whether a progestogen is included, why it is needed, and how the proposed regimen fits the patient’s cardiovascular history.

What the assessment can and cannot establish

A cardiovascular assessment before systemic HRT can identify factors that change the balance of risk. It can also clarify whether a different route or a delay while risk factors are brought under control is warranted. It cannot guarantee an individual outcome, and it should not be used to claim that HRT prevents cardiovascular disease.

Professional guidance from major obstetric, menopause, and cardiology organizations advises against prescribing HRT for primary or secondary prevention of cardiovascular disease. In other words, systemic hormone therapy should not be started to prevent a first heart attack or to prevent another event in someone who already has cardiovascular disease. Questions about treatment after a myocardial infarction or in established coronary disease require specialist, individualized assessment; the available evidence does not support a simple universal rule for every regimen and patient.

This also defines the limits of claims about cardiovascular benefits of early menopause treatment. Earlier initiation in an otherwise healthy woman may be associated with a more favorable cardiovascular benefit-risk profile when HRT is used for menopausal symptoms. That is different from evidence that treatment prevents heart disease. Symptom treatment and cardiovascular prevention are separate clinical goals.

For heart disease prevention in postmenopausal women, the assessment should not stop at the HRT decision. Blood pressure, lipid abnormalities, diabetes, smoking, and other established cardiovascular risks need their own evidence-based management. HRT does not replace that care.

The evidence-based bottom line

Before starting systemic hormone therapy, establish the indication, the time since menopause, age, cardiovascular history, blood pressure, lipid profile, and overall 10-year cardiovascular risk. A risk of 10% or higher, blood pressure at or above 180/110 mmHg, total cholesterol above 7.8 mmol/L, or triglycerides above 4.5 mmol/L are significant findings that call for careful review.

For healthy women younger than 60 or within 10 years of menopause, systemic HRT used for symptoms generally has a favorable benefit-risk profile. Later initiation is associated with higher cardiovascular and thromboembolic risks. Transdermal estradiol has lower associated risks of venous thromboembolism and stroke than oral estradiol, and non-androgenic progestogens have a more favorable or neutral vascular-risk profile than synthetic androgenic options.

The decision is specific to the patient and the regimen. HRT is a treatment for menopausal symptoms, not a strategy for preventing heart disease.